We analyzed clinical and pathological disease in 2 peripheral myelin protein-22 (PMP22) overexpressing mouse models for 1.5 years. C22 mice have 7 and C3-PMP mice have 3 to 4 copies of the human PMP22 gene. C3-PMP mice showed no overt clinical signs at 3 weeks and developed mild neuromuscular impairment; C22 mice showed signs at 3 weeks that progressed to severe impairment. Adult C3-PMP mice had very similar, stable, low nerve conduction velocities similar to adults with human Charcot-MarieTooth disease type 1A (CMT1A); velocities were much lower in C22 mice. Myelination was delayed, and normal myelination was not reached in either model but the degree of dysmyelination in C3-PMP mice was considerably less than that in C22 mice; myelination was stable in the adult mice. Numbers of myelinated, fibers were reduced at 3 weeks in both models, suggesting that normal numbers of myelinated fibers are not reached during development in the models. In adult C3-PMP and wild-type mice, there was no detectable loss of myelinated fibers, whereas there was clear loss of myelinated fibers in C22 mice. In C3-PMP mice, there is a balance between myelination status and axonal function early in life, whereas in C22 mice, early reduction of axons is more severe and there is major loss of axons in adulthood. We conclude that C3-PMP mice may be an appropriate model for most CMT1A patients, whereas C22 mice may be more relevant to severely affected patients in the CMT1 spectrum.
INTRODUCTION
Charcot-Marie-Tooth disease type 1A (CMT1A), also called hereditary motor and sensory neuropathy type Ia (HMSN Ia), is the most prevalent hereditary demyelinating neuropathy (1) . In most cases, this autosomal, dominantly inherited disease is related to a 1.5-Mb duplication on chromosome 17p that includes the peripheral myelin protein 22 (PMP22) gene (2, 3) . Point mutations in this gene are a rare cause of CMT1A, and these forms are currently also known as CMT1E (4, 5) . PMP22 is a tetraspan glycoprotein contained in compact myelin of the peripheral nervous system. There is also evidence that PMP22 is involved in the interaction of the Schwann cells with the extracellular environment (6) . The molecular mechanisms underlying CMT1A are not well understood and are probably different for the most prevalent form in which there are 3 copies of PMP22 and the rare forms due to point mutations in PMP22 (7). Impaired intracellular protein trafficking, inefficient degradation, and formation of aggregates may play a role in pathogenesis (8, 9) . Recently, several studies reported genetic rearrangements other than the ''classic'' duplication and point mutations in PMP22, that affect PMP22 expression and which may be important in delineating the expression and function of PMP22 (10Y13).
In humans, symptoms and signs of predominantly distal loss of strength and sensation, more in the legs than in the arms, often develop in the first 2 decades of life (14) . For many years, there has been debate as to whether, and to what extent, adult patients deteriorate. We and others have hypothesized that clinical disease progression could be due to increased axonal dysfunction, secondary to a fairly stable myelination status (15Y17). Longitudinal studies with a follow-up of 2 to 5 years showed clinical progression in adults (17Y19), with indications for increased axonal dysfunction over time, as assessed indirectly with compound muscle action potential (CMAP) amplitudes recorded with surface electrodes (17, 19) . The decline in surface CMAP amplitudes and in muscle strength in adult patients was, however, in the same range as that in healthy people, so we postulated that this decline reflects to a considerable extent a process of normal aging (19) . This finding is supported by a study that used a motor unit number estimation technique in a large group of adult CMT1A patients and which showed that the age-dependent decrease in the number of motor units did not differ between patients with CMT1A and controls, indicating that loss of motor units in adult patients is limited (20) . A reliable mouse model for CMT1A is important not only to clarify the molecular mechanisms underlying CMT1A but also for experiments with disease-modifying treatments in preclinical studies. Several transgenic mouse models for dys/demyelinating peripheral hereditary neuropathies have been generated that resemble human CMT1A (21Y24), although none are perfect in this regard (24) . Several experiments involving animal models for CMT1A and using nerve grafts from patients with CMT1A showed different degrees of abnormal myelination, as well as axon pathology. Studies of trembler mice, which have a point mutation in Pmp22, were one of the first to address the issue of axon pathology. Nerve transplants of trembler mice produced local biochemical changes in axons that have regenerated through them, including alterations in neurofilament phosphorylation, increased neurofilament density, and decreased axonal transport (25, 26) . Mice carrying approximately 16 and 30 Pmp22 copies showed a reduced number of axons at 12 months, but other time points were not documented (22, 27) . Mouse axons that regenerated through nerve grafts from patients with CMT1A had a reduced caliber compared with surrounding nerves (28) . Because detailed follow-up studies are scarce, it is unclear whether disease progression in these mouse models is similar to the progression in humans with CMT1A.
The aims of this study were to determine the course of the disease in 2 PMP22-overexpressing mouse models, clinically, electrophysiologically, and morphometrically for 1.5 years and compare the changes with wild-type (WT) mice. These findings were then compared with data obtained during a recently completed and published natural history study in CMT1A patients to clarify whether these PMP22-overexpressing mice are useful models (19) .
MATERIALS AND METHODS

Animals and Determination of Genotypes
The animal experimental committee of the Academic Medical Center, Amsterdam, approved the experiments. C22 mice in a C57BL/6J Â CBA/Ca background, carrying 7 copies of a YAC containing the human PMP22 gene (21) , were backcrossed to a C57BL/6J wild-type (WT) strain (Harlan Laboratories, Horst, The Netherlands) for more than 10 generations to minimize the influences of genetic modifiers. Genotyping of WT and C22 mice was determined by conventional polymerase chain reaction (PCR) after extraction of mouse DNA from a sample of ear tissue. Primers used for amplification of the human PMP22 transgene were CTTCAGGCCC TGCACCTC and CATTCCGCAGACTTGGATG.
After breeding C22 mice for more than 10 generations to a C57BL/6J background, 3 mice (1 male and 2 females) in a litter of 8 were observed to show a milder phenotype. These mice, which we named C3-PMP, were bred separately. Using quantitative real-time PCR, we showed that C3-PMP mice had a stable genotype with a reduced human PMP22 copy number compared with the C22 mice. The quantitative real-time PCR was performed on a LightCycler 480 system using Universal Probes according to the manufacturer's protocol for monocolor hydrolysis probe (Roche Diagnostics, Mannheim, Germany; http://www.roche-applied-science.com/lightcycler-online/). Samples of 15 C3-PMP mice, from all generations used in the experiment, were assayed in triplicate on 4 dilutions (2.5, 5, 10, and 20 ng of DNA input). Quantification was performed using the Roche LightCycler software for crossing point calculation with an assumed PCR efficiency of 2. The endogenous mouse Pmp22 amplification was used as reference for DNA input. The results of C3-PMP mice were compared with C22 mice with 7 (to 8) copies of the human PMP22. We found a consistent difference in crossing point between C3-PMP, from all generations used in the experiments, and C22 mice (Figure, Supplemental Digital Content 1, http://links.lww.com/NEN/A231). With this, we calculated that the C3-PMP mice had 3 (to 4) copies of the human PMP22. Primer sequences used for LightCycler 480 reactions (gene, forward primer, reverse primer, universal probe number, respectively) were human PMP22: TCAG GAAATGTCCACCACTG, CAAGCTCATGGAGCACAA AA, no. 9; mouse Pmp22: GGGAATGGCTTGCTGATCT, TGGTATTCCCCAGCCTCAT, no. 51. All primers used were purchased form from Sigma-Aldrich, Zwijndrecht, The Netherlands, and Universal Probes were purchased from Roche Diagnostics.
Neuromuscular SHIRPA
A modified version of the Smith Kline Beecham, MRC Harwell, Imperial College, the Royal London Hospital phenotype assessment (SHIRPA) protocol (29) , was used to give an overall assessment of neuromuscular function. This included 19 items of the original SHIRPA protocol and an additional item. With the mouse in the viewing jar, body position, spontaneous activity, tremor, and, the extra item, letting the limbs slip through the grid were scored. The scores in the arena were for transfer arousal, gait, pelvic and tail elevation, and touch escape. Above the arena, positional passivity, trunk curl, limb grasping, grip strength, body tone, and toe pinch were scored. Limb tone and abdominal tone were scored during supine restraint. The wire maneuver, negative geotaxis, and contact-righting reflex were scored with a wire, a tube, and a grid, respectively. A sum score was calculated ranging from 0 indicating no signs and 43 being maximally affected. Locomotor activity in the arena during 30 seconds was scored separately.
Electrophysiology
Mice were anesthetized with an i.p. injection of fentanylfluanizone-midazolam mixture (1 mL of Hypnorm [Janssen, Beerse, Belgium], 1 mL of midazolam [Roche, Mijdrecht, The Netherlands], and 2 mL of water). Temperature was maintained above 34-C. The hind legs and the tail were strapped to a polystyrene board. The sciatic nerve and caudal nerve were studied on 1 side on a Viking I EMG machine (Nicolet, Madison, WI). For motor conduction studies of the sciatic nerve, monopolar needle electrodes were inserted as follows: the stimulating cathodes were placed at the medial ankle and at the sciatic notch, the stimulating anode was inserted 3 mm distal to the stimulating cathode, the recording cathode was placed i.m. between the hallux and the second digit and the anode was inserted laterally at the fifth digit, and an earth electrode was attached halfway between the distal stimulating and recording electrodes. Supramaximal squarewave pulses of 0.1-millisecond duration were delivered and CMAP amplitudes (peak to peak) were recorded. Motor nerve conduction velocities (MNCVs) over the segment between the ankle and the sciatic notch were calculated. For studies of the caudal nerve, monopolar needle electrodes were inserted as follows: the stimulating cathode was placed laterally in the tail at exactly 2 cm from the base of the tail, the stimulating anode was inserted 3 mm distal to the stimulating cathode, the recording cathode and anode were inserted at the base of the tail just 3 mm apart, and the earth electrode was attached halfway between the stimulating and recording electrodes. Supramaximal square-wave pulses of 0.5-millisecond duration were delivered. A maximum of 30 responses were averaged for each recording. Compound nerve action potentials (CNAPs) amplitudes (peak to peak) were recorded. The nerve conduction velocity (NCV) of the tail nerve was calculated from the latency of the stimulus artifact to the onset of the negative peak of the action potential elicited and the distance between the stimulating and the recording cathodes.
Histology and Morphometry
In deeply anesthetized mice, the chest was opened, and blood was flushed out with saline via a cannula inserted into the left ventricle of the heart followed by fixative (4% paraformaldehyde in phosphate-buffered saline). The nerves were removed and further fixed in 1% paraformaldehyde plus 1% glutaraldehyde in 0.1 mol/L of PIPES buffer (Sigma-Aldrich, Poole, UK) overnight. Samples were processed conventionally into Durcupan resin (Sigma-Aldrich) for light and electron microscopy (30) . The sections examined were taken from the peroneal nerve, the motor branch of the femoral nerve, and the lumbar ventral and dorsal roots. For light microscopy (Zeiss UK, Welwyn Garden City, UK) and morphometry, 0.5-Km sections were cut and stained with thionine (VWR, Lutterworth, UK) and acridine orange (Molekula, Shaftesbury, UK). For electron microscopy (Zeiss SMT, Cambridge, UK), ultrathin sections (70 nm thick) were counterstained with methanolic uranyl acetate and lead citrate (both from Agar Scientific, Stansted, Essex, UK). Histology assessment was undertaken with a combination of high-magnification light microscopy using Â100 oil immersion lens and electron microscopy. Sections were examined for pathological changes including signs of active demyelination and remyelination, abnormally thin myelin, onion bulbs, active axonal degeneration and regenerative clusters, and the presence of uncompacted myelin.
Morphometry was performed using a Zeiss Axioplan microscope (Zeiss UK) fitted with a Märtzhäuser motor driven stage (Imaging Associates, Bicester, UK) connected to computer running Zeiss KS400 software (Imaging Associates). The entire cross-sectional areas of the nerves were analyzed using Â100 oil immersion lens. Myelinated fibers were defined as having axons with a diameter large enough to be myelinated, which was defined as 2 Km or greater. These fibers were quantified and divided in normally myelinated, thinly myelinated, and amyelinated fibers based on their g-ratios (ratio of the axon diameter to the total fiberYaxon plus myelin diameter). A g-ratio of 0.7 was considered normal. A reference image showing a series of annuli from 2 to 14 Km in diameter with a wall thickness indicating a g-ratio of 0.7 was incorporated into the measurement program. Normally myelinated fibers were defined as fibers with a myelin sheath thickness that was appropriate for axon diameter (g-ratio e0.7). Thinly myelinated fibers were defined as fibers with a myelin sheath thinner than appropriate (g-ratio 90.7). Amyelinated fibers were defined as fibers large enough to be myelinated but having no myelin sheath resolvable by light microscopy. These 3 categories (normal, thinly myelinated, and amyelinated) when summed are together referred to as myelinated fibers for brevity. Unmyelinated fibers, which had a diameter less than 2 Km and no visible myelin sheath, were not analyzed. The software used for morphometry automatically segmented the myelinated fibers and allowed for manual modifications, such as the addition of fibers with no myelin sheath resolvable by light microscopy. Axonal diameters were derived from myelinated FIGURE 1. Neuromuscular Smith Kline Beecham, MRC Harwell, Imperial College, the Royal London Hospital phenotype assessment (SHIRPA) sum score as a composite measure of impairment for 72 weeks in wild-type (WT), affected C3-PMP and more affected C22 mice. Bars indicate means; error bars indicate SD; numbers of mice analyzed per group are indicated. The sum score ranges from 0 to 43, with 0 indicating normal performance and 43 maximally affected. Young C22 mice (3 weeks) performed significantly worse on the SHIRPA than young WT and C3-PMP mice; WT and C3-PMP mice did not differ (unpaired t-tests). The sum scores increased significantly between 3 and 24 weeks in the C3-PMP and C22 mice but not the WT mice, indicating a decreased performance on the SHIRPA in the former (ANOVA, post hoc Bonferroni). The mean sum scores in the adult C3-PMP and C22 mice (Q24 weeks) were significantly higher than those in the WT mice; those in the C22 mice were higher than in the C3-PMP mice (unpaired t-tests).
fiber diameters by subtracting the myelin thickness (calculated from the g-ratio).
Statistical Analysis
Mouse characteristics, data from the modified SHIRPA, electrophysiological examination, and morphometry were analyzed using descriptive statistics. In WT, C3-PMP and C22 mice, changes between 3, 24, 48, and 72 weeks were evaluated with analysis of variance (ANOVA), with a post hoc Bonferroni correction for multiple comparisons. Differences between young (3 weeks) WT, C3-PMP, and C22 mice and differences between adult (Q24 weeks) WT, C3-PMP, and C22 mice were evaluated with unpaired t-tests. For adult mice (Q24 weeks), associations were studied between the neuromuscular SHIRPA, and electrophysiological and morphometric parameters (Spearman correlation coefficient). Owing to the difficulty of the electrophysiological measurements, this was not successful on all mice. All analyses were done with SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL).
RESULTS
Neuromuscular SHIRPA
Neuromuscular SHIRPA scores in both the C3 and C22 mice increased significantly from week 3 to 24, indicating a decrease in performance. Adult C22 mice (Q24 weeks) were most severely affected (n = 38, 15.1 T 3.8 [mean T SD], p G 0.001); C3-PMP mice had intermediate scores (n = 27, 5.1 T 2.9, p G 0.001) compared with WT mice (n = 31, 1.5 T 1.0) (Fig. 1) . Values of the individual scores are given in the Table, Supplemental Digital Content 2, http://links.lww.com/NEN/A232. Items contributing most to the overall score (mean Q1.0 for C22) were tremor, gait, tail elevation, touch escape, grip strength, and wire maneuver. Locomotor activity was less in adult C3-PMP mice (n = 27, 9.0 T 3.8 fields, p = 0.02) and C22 mice (n = 38, 8.2 T 4.8 fields, p = 0.001) versus WT mice (n = 31, 13.9 T 8.9 fields), with no difference between C22 and C3-PMP mice.
Electrophysiology
Mean NCVs were lower in C3-PMP and in C22 mice than in WT mice at all ages and also lower in C22 than in C3-PMP mice at all ages (Table 1 ). All mouse strains showed an increase in mean (M)NCVs from 3 to 24 weeks, after which there was no further change. The MNCV of the sciatic nerve (tibial division) was 21.5 T 5.4 in adult C3 mice (n = 24), 4.6 T 0.7 in adult C22 mice (n = 35) and 41.1 T 4.9 in adult WT mice (n = 26). Young C3-PMP and WT mice had needle CMAPs of the intrinsic foot muscles similar in mean amplitude; adult C3-PMP mice had lower mean CMAP amplitudes than WT mice. C22 mice had lower mean CMAP amplitudes than C3-PMP and WT mice at all ages tested. Mean CNAP amplitudes over the tail were lower in C3-PMP and C22 mice than in WT mice, regardless of age. Mean CNAP amplitudes were lowest in C22 mice. Mean CNAP amplitudes decreased significantly from 3 to 48 and 72 weeks in the C22 mice but not in the C3-PMP and WT mice. 
Electrophysiological measurements of the sciatic nerve (tibial division) and the caudal nerve for WT, C3-PMP, and C22 mice (mean T SD). Changes over time between 3, 24, 48, and 72 weeks were tested separately for WT, C3-PMP and C22 mice (ANOVA, post hoc Bonferroni). Differences between the models at 3 weeks (''Young'') and at 24 weeks or older (''Total adult'') were tested (unpaired t-tests).
Significant differences are shown (p G 0.05). CMAP, compound muscle action potential amplitude (mV); CNAP, compound nerve action potential amplitude (KV); (M)NCV, (motor) nerve conduction velocity (m/s); WT, wild-type.
The peroneal nerve, the motor branch of the femoral nerve, and the lumbar ventral and the dorsal roots were examined by light microscopy (Fig. 2) . Sections of 21 C22, 5 C3-PMP, and 10 control mice were also examined by electron microscopy (Fig. 3) . In C3-PMP and C22 mice, there were numerous inappropriately thinly myelinated and amyelinated fibers in the peroneal nerve at 3 weeks compared with WT mice; this was most marked in the C22 mice and to a lesser degree in the C3-PMP mice (Figs. 2AYC) . The numbers of normally myelinated fibers in the C3-PMP and C22 mice increased from 3 weeks to adulthood, although this never became the same as in WT mice. In adulthood, the C22 mice remained more severely affected than the C3-PMP mice (Figs. 2DYF). The incidence of inappropriately thinly myelinated and amyelinated fibers was more variable in the C3-PMP mice than in the C22 mice, both between C3-PMP mice of the same age and between different nerves in individual C3-PMP mice. There seemed to be a greater proportion of inappropriately thinly myelinated and amyelinated fibers in the motor branch of the femoral nerve (Figs. 2GYI) versus the peroneal nerve (Figs.  2DYF) . In both models, the lumbar ventral roots had an even higher proportion of these fibers (Figs. 2JYL) compared with the dorsal roots (Figs. 2MYO) and the peripheral nerves.
The most important electron microscopy findings are shown in Figure 3 . Many amyelinated and very thinly myelinated fibers were found in both strains as well as many smalldiameter fibers that were hypermyelinated (Figs. 3A, B) . Partially or completely uncompacted myelin sheaths were often present in the peripheral nerves (Figs. 3B, C, I ) (31), but not in the roots, in C22 mice; this abnormality was not found in C3-PMP mice. Occasionally, demyelinated axons accompanied by myelin debris in the associated Schwann cell, suggesting active myelin breakdown, were identified in nerves and roots at all ages in C22 mice but only rarely in C3-PMP mice (Fig. 3D) . Small onion bulb formations indicating repeated episodes of demyelination and remyelination were only rarely seen in C22 (Fig. 3E) but not in C3 mice. Some fibers were remyelinated in both models.
At all ages, there were occasional atrophic fibers (Fig. 3A) , signs of early axonal degeneration (Fig. 3F ) (32, 33) , and attenuated Schwann cell processes indicating fiber loss (Fig. 3G) . These abnormalities were much more frequent in C22 mice than in the C3-PMP mice. Debriscontaining macrophages were sometimes seen in C22 mice (Fig. 3D ) but were very rarely found in C3-PMP mice. Some sequestration of axon organelles by Schwann cells, implying axonal damage, was occasionally found (Fig. 3H) (34) . Regenerative clusters of myelinated fibers were not identified in either model. Remak fibers were often abnormal with an increase in membranous structures in both strains. Occasionally, even in older animals, some had abnormally large numbers of small axons and also contained larger axons suggesting a block at the promyelination stage (Fig. 3I) . None of these abnormalities were found in WT mice apart from some indication of axonal sprouting in a 72-week-old WT mouse and 3 demyelinated fibers in another 72-week-old WT mouse.
The peroneal nerve and the motor branch of the femoral nerve were used for morphometric analysis. Morphometry of the peroneal nerve was performed in 3-, 24-, 48-and 72-week-old mice ( Fig. 4A; Table 2 ). In WT mice of all ages, the number of myelinated fibers in the peroneal nerve remained stable, that is, approximately 1066 T 61 (n = 37, 3Y72 weeks). By 3 weeks, virtually all these fibers were normally myelinated in WT mice (n = 6). In C3-PMP mice, the number of myelinated fibers (including normally myelinated, inappropriately thinly, and amyelinated fibers) was 986 T 76 (n = 34, 3Y72 weeks), which was slightly lower than in WT mice (p = 0.04) and was fairly stable up to 72 weeks. The percentage of fibers that were normally myelinated in C3-PMP mice was 74% at 3 weeks, increased to around 84% at 24 weeks, and then remained stable. In C22 mice, owing to the small diameter of most fibers at 3 weeks (see below) and the lack of collagen separating them, it was difficult to discriminate between myelinated fibers (with a diameter Q2 Km but no myelin sheath) and unmyelinated fibers. With this limitation, the number of myelinated fibers was low in 3-week-old C22 mice (n = 11, 767 T 114). By 24 weeks, this number had increased slightly (n = 11, 873 T 79, p = 0.07) but then showed a decline at 48 weeks (n = 14, 720 T 104, p = 0.001) and at 72 weeks (n = 13, 572 T 72, p = 0.001). The percentage of normally myelinated fibers was 40% at 3 weeks, increased up to approximately 64% in adult mice, and then remained stable.
Morphometry of the motor branch of the femoral nerve was performed in 48-week-old animals (Fig. 4B) . The number of myelinated fibers in the motor branch of the femoral nerve did not differ between C3-PMP mice (n = 11, 554 T 46) and WT mice (n = 6, 571 T 23, p = 0.42). C22 mice had a lower number of myelinated fibers (n = 6, 365 T 63) versus the WT (p G 0.001) and C3-PMP (p G 0.001) mice. The percentages of normally myelinated fibers were approximately 75% in the C3-PMP mice and 40% in the C22 mice, which is lower than in the peroneal nerve in both models. Representative microphotographs of thionine-and acridine orangeYstained 0.5-Km-thick sections demonstrate differences in myelination in the genotypes at different ages and at different sites in the peripheral nerves and in the roots. (AYO) The genotypes are presented in the columns (WT, C3-PMP, and C22). Peroneal nerve sections at 3 (AYC) and at 48 weeks (DYF); motor branch of the femoral nerve at 48 weeks (GYI); ventral roots at 48 weeks (JYL), dorsal roots at 48 weeks (NYO). In C3-PMP and more severely in C22 mice, the degree of myelination in the peroneal nerve was reduced at 3 weeks compared with WT mice (AYC). The degree of myelination improved over time, although it never became the same in the C3-PMP and C22 mice as in WT mice. The C22 mice remained more severely affected than the C3-PMP mice (DYF). The myelin of the motor branch of the femoral nerve (GYH) was more abnormal than the myelin of the peroneal nerve (DYF). In both models, abnormal myelination was most prominent in the lumbar ventral roots (JYL) compared with the myelination of the dorsal roots (MYO) and the peripheral nerves. Scale bar = 20 Km. WT = wild-type.
Median axon diameters were calculated by subtracting the calculated myelin thickness from the measured fiber diameter. The mean median axon diameters in the peroneal nerve in WT mice increased from 3.9 T 0.1 Km at 3 weeks (n = 4) to 6.0 T 0.4 Km at 24 weeks (n = 4) and 6.4 T 0.4 Km at 48 weeks (n = 4). The mean median axon diameters in C22 mice increased from 2.6 T 0.3 Km at 3 weeks (n = 4) to 3.6 T 0.1 Km at 24 weeks (n = 4) and 4.3 T 0.1 Km at 48 weeks (n = 4). At all these time points, the differences between WT and C22 were significant (p G 0.001). The mean median axon diameters in the motor femoral nerve in WT mice was 7.3 T 0.2 Km (n = 4) and in C22 mice 3.7 T 0.7 Km (n = 4, p G 0.001) at 48 weeks.
Associations Between Clinical Disease Severity and Electrophysiological and Morphometric Parameters
In adult (Q24-week-old) mice, higher neuromuscular SHIRPA sum scores were associated with lower numbers of myelinated fibers, lower numbers of normally myelinated fibers, and lower needle CMAP amplitudes (Fig. 5) . Lower sciatic nerve MNCVs were associated with higher neuromuscular SHIRPA sum scores, lower numbers of myelinated axons, and lower needle CMAP amplitudes. All of these associations were highly significant (p G 0.001).
DISCUSSION
We studied the disease course during 1.5 years in 2 different PMP22-overexpressing mouse models. The C3-PMP mice with 3 to 4 copies of the human PMP22 gene showed no overt clinical signs at 3 weeks and developed mild neuromuscular impairment, whereas the C22 mice with 7 copies of the human PMP22 showed signs at 3 weeks that progressed to severe impairment. Table 3 summarizes similarities and differences between these mice and human CMT1A with regard to myelin and axonal pathology.
One of the hallmarks of human CMT1A is low NCVs, the electrophysiological surrogate marker for myelin status. Nerve conduction velocities in young child patients never reach normal adult values (39Y41), as in the PMP22-overexpressing models. In adult CMT1A patients, NCVs are stable and do not deteriorate with age (17, 19) , also as in the PMP22-overexpressing models. Moreover, the NCVs in adult C3-PMP mice are in the same range as those in adult CMT1A patients. Thus, axons are surrounded by functional myelin over a considerable portion of nerve length in both humans and C3-PMP mice. The very low NCVs in the C22 mice (which have previously been reported [21] ) are in the range of NCVs found in unmyelinated axons (36, 42) . Because the velocities of the fastest conducting axons are measured, this suggests that myelin is lacking over most of the internodes along the length of the nerve thereby explaining the very low NCVs in the C22 mice.
The limited pathological data in human CMT1A suggest that dysmyelination may be of major importance (37, 43Y47). In both PMP22-overexpressing mouse models, myelination was delayed and normal myelination was never achieved. Consistent with the differences in NCVs between the C3-PMP and C22 mice, the degree of dysmyelination in C3-PMP mice was considerably less in the C3-PMP than in C22 mice. Severe dysmyelination was reported previously in C22 mice (38) . In both mouse models, amyelinated or thinly The mean numbers of myelinated fibers in the peroneal nerve in young (3 weeks) and in adult (Q24 weeks) C3-PMP and C22 mice were significantly lower than those in the WT mice; those in the C22 mice were lower than in the C3-PMP mice (unpaired t-tests). In C22 mice, the mean number of myelinated fibers decreased significantly between 24, 48, and 72 weeks (ANOVA, post hoc Bonferroni). (B) The number of myelinated fibers in the motor branch of the femoral nerve did not differ between 48-week-old C3-PMP and WT mice; C22 mice had a lower number of myelinated fibers versus WT and C3-PMP mice (unpaired t-tests). myelinated fibers were most abundant in the ventral roots; they were less abundant in the motor femoral quadriceps nerve and even less in the dorsal roots and the mixed motorsensory peroneal nerve (Fig. 2) . In WT mice, the ventral root consists for approximately 75% of large myelinated axons (30) , whereas the motor femoral and peroneal nerves are more mixed with larger numbers of small fibers in the peroneal than in the motor femoral nerve. The sensory femoral consists mainly of small fibers and is very mildly affected. Hence, the variation in degree of dysmyelination in the mice could be due to the different fiber size distributions at the different sites, indicating that dysmyelination predominantly affects larger diameter fibers rather than whether they are motor or sensory in origin. This is also found in other CMT1 mouse models such as myelin protein zero (Mpz)Ydeficient mice in which the authors suggested that dysmyelination might be related to the different structure of nodes in large versus small fibers (48) . Uncompacted myelin sheaths are not seen in human CMT1A or in the C3-PMP mice, but this abnormality was often present in the C22 mice (Figs. 3B, C, I ). This also has been previously reported for C22 mice and for other mouse models in which PMP22 expression is markedly affected such as C61 j/j , Trembler J, and My41 mice (24, 30, 49) , but also for models for other forms of CMT, such as Mpz-deficient mice (48) . In view of the close association of PMP22 and MPZ in the myelin structure, altering the proportion of either may have the same deleterious effect. Longitudinal sections suggested that uncompacted myelin occurs mainly in the paranodal region and may be related to a difficulty in producing the major dense line of compact myelin in these myelin mutants (data not shown).
Unlike the mouse models, demyelination is more prominent in human CMT1A. Active demyelination was identified in early childhood in CMT1 patients with infantile onset (43) but not further specified in a later article specifically addressing CMT1A (44) . The presence of debris-containing macrophages indicated a low level of ongoing, active demyelination throughout life that was more prominent in C22 than in C3-PMP mice. A proportion of the thinly myelinated fibers was probably the result of demyelination and remyelination. The paucity of onion bulb formations in these, but also other mouse models (24) compared with patients with CMT1A (44, 45), may reflect a higher degree of active demyelination and remyelination during the first years of life in humans (44) , be related to the shorter life span of mice, or some other difference between mice and humans. It is of interest onion bulbs were not found in dermal myelinated fibers in adult CMT1A patients (47) , in contrast to the sural nerve.
Morphometric studies show that axon numbers in both CMT1A patients and in the PMP22-overexpressing mouse models are lower than in healthy controls, but studies in humans are scarce and limited to sensory nerves. Morphometry studies of the sural nerve early in life (the youngest child studied being 2 years) suggest fewer myelinated fibers (44) . These data should be interpreted with caution because studies were performed in a small number of young patients and did not assess the total myelinated fiber population in all fascicles; the total myelinated fiber number was calculated from areas Morphometry of the peroneal nerve for WT, C3-PMP, and C22 mice (mean T SD). Changes over time between 3, 24, 48 , and 72 weeks were tested separately for WT, C3-PMP, and C22 mice (ANOVA, post hoc Bonferroni). Differences between the models at 3 weeks (''Young'') and at 24 weeks or older (''Total adult'') were tested (unpaired t-tests).
Significant differences are shown (p G 0.05). *, p = 0.05. WT, wild-type.
and fiber densities (which are affected by the increase in Schwann cell processes and in fibrous endoneurial collagen) (44) . Nonetheless, this would be in accordance with the early lower number of myelinated fibers found in the mouse models. Similarly to the developmental studies, detailed investigations of the sural nerve in adult CMT1A patients comprise only small numbers; therefore, it is difficult to draw conclusions about axonal loss over time (44) . This caveat also applies to morphometric studies in the sural nerve in healthy controls (50); a wide variation in myelinated fiber density and total fiber numbers in a limited number of healthy controls makes a proper estimate of the decline over time very difficult. In a recent study, the number of dermal myelinated fibers was quantified by measuring the density of Meissner corpuscles, showing lower densities in adult CMT1A patients than in controls (47) . As early as 3 weeks, C3-PMP mice showed reduced numbers of normally myelinated fibers in the peroneal nerve compared with WT. These numbers were even lower in C22 mice. During adulthood, there was no detectable loss of myelinated fibers in the peroneal nerve in C3-PMP mice and WT mice, indicating that axons are preserved to a similar extent in both adult WT and C3-PMP mice, whereas there was a clear loss in C22 mice in this nerve. Documenting changes in axon diameter over time as another indicator of the long-term axonal integrity might be informative. Median axon diameters in the peroneal nerve were smaller at all ages in C22 mice compared with WT mice, but there were no evidence of a reduction in median diameter over time in adult mice. Therefore, it is unlikely that there would be a reduction over time in axon diameter in the less affected C3-PMP mice. Data in human CMT1A suggest that the severity of the disturbance of the myelination process is a factor that eventually determines the extent of axonal dysfunction in the first 2 decades of life (19) . After the nerves have reached their final length, a balance may be reached between myelination status and axonal function. Studies showed the intimate interaction between developing axons and myelin (51Y54). It might be hypothesized that an abnormal axonYSchwann cell interaction early in life reduces the number of axons that become large enough to be myelinated, that is, that normal numbers of myelinated fibers are never reached. Our results in the mouse models suggest that severely abnormal myelination leads to more axonal dysfunction, which is also dependent on the length of the nerve. Early degeneration and loss of dysmyelinated axons may be another explanation, although we observed no pathological evidence for this here. The results in adult mice may still reflect the amount of axonal dysfunction that arose earlier in life due to the abnormal myelination. Indeed, clinically more affected adult mice with higher neuromuscular SHIRPA sum scores showed lower needle CMAP amplitudes, lower numbers of (normally) myelinated fibers and lower MNCVs. As in human CMT1A, the results in C3-PMP mice indicate that a balance is reached between myelination status and axonal function early in life whereas in C22 mice the early reduction of axons is more pronounced with more marked loss of axons in adult mice.
The notice of the importance of axonal involvement in dys/demyelinating hereditary neuropathies has arisen not only in CMT1A and its animal models but also in the other types such as CMT1B. Myelin protein zero is an adhesion molecule in the Schwann cell membranes and has an important role in myelin compaction. Certain point mutations in the MPZ gene have as a prominent feature that myelination is disturbed during development (CMT1B), but in humans and in a CMT1B mouse model, there is also evidence of axonal degeneration (55) . Other mutations in MPZ lead to more subtle changes in the myelin structure in which a disturbance of Schwann cellYaxon interactions mainly leads to axonal degeneration (CMT2I and J) (56) . A role for axonal involvement is also seen in X-linked CMT, which is caused by point mutations in the GJB1 gene encoding connexin 32 (Cx32). Cx32 is a gap junction protein present in noncompact myelin, that is, the paranodal regions and the Schmidt-Lanterman incisures (57) . In males, this mutation often leads to a demyelinating neuropathy with a relatively severe disease course, whereas females more often have an axonal form that is clinically less severe and sometimes asymptomatic (58) . In Gjb1-null mice, which develop a progressive demyelinating peripheral neuropathy after 3 months (59), it was recently shown that axonal pathology even precedes the first signs of demyelination (35) .
The strengths of this study include its duration, the investigation of different disease severities, and the relatively large groups of mice. Ideally, longitudinal assessment of the same mice would have been an optimal design to trace changes over time. Because the morphometric analysis is invasive, however, we had to study different mice at several time points. Despite this, because of the stable genetic background, we do not believe that we may have missed relevant changes. Needle CMAP recordings, which were done because of the small size of the mice at 3 weeks, may have limitations because they represent a relatively small area of the recorded muscle; thus, they may not as readily detect small changes in axonal function over time as surface recordings. The duration of the study does not span the life of a mouse but 1.5 years extends well into adult mouse life, and in this period, progressive changes in numbers of axons were detectable in the C22 mice. We do not expect that a longer duration of the study would change our conclusions. The endogenous mouse Pmp22 as well as the transgenic human PMP22 are expressed in the mouse models. Previous studies determined the level of expression of the human PMP22 transgene relative to the level of mouse Pmp22 mRNA and found that higher ratios were associated with a more severe polyneuropathy. The ratio was 1.6 for the C22 model with 7 copies of the human PMP22 gene and 1 for a model with 4 copies of the transgene (49) . However, these measurements were performed on affected nerves containing a relatively high proportion of nonmyelinating cells. Therefore, we think that these measurements may underestimate the extent of overexpression of PMP22 mRNA. It is difficult to extrapolate these ratios to the situation in human CMT1A because absolute PMP22 amounts cannot be deduced from the mRNA ratios, nonmyelinating Schwann cells also produce PMP22 mRNA, and a major part of PMP22 is degraded normally (60) . Theoretically, the human PMP22 duplication would lead to a 1.5-times increase in PMP22 mRNA expression. The density of PMP22 in compact myelin from CMT1A nerves in human skin biopsies was elevated around 2 times on average but highly variable between patients (61). In our opinion, the resultant polyneuropathy in terms of clinical symptoms and signs, together with the electrophysiology and pathology, should be the major criterion to judge the usefulness of the mouse models. Because the original C22 line was kept on a mixed background, genetic modifiers (which might influence the severity of the disease) would not be equally present in all offspring. Therefore, we first performed a backcross of the C22 line to the C57BL/6J background for 10 generations. We cannot exclude the possibility that (even in a stable genetic background) the level and timing of PMP22 expression is critical and that this may lead to neuropathological variability, as found in the C3-PMP mice. There are some parallels with human CMT1A: the severity of clinical signs and symptoms may vary widely, between as well as within families (62) . Genetic variability in humans cannot be the only explanation because, even between identical twins, there is variability in clinical signs and CMAP amplitudes, indicating that axonal dysfunction is also variable (63) . The intramouse variability may be intriguing at first sight, but again, there are some parallels to human CMT1A: although biopsy material is scarce, there already is considerable neuropathological variability reported between dermal nerves and sural nerves. Because distal and proximal motor nerves are not examined by biopsy, we are not informed about their variability in humans.
To our knowledge, this is the first study that quantifies the course of the disease clinically, electrophysiologically, and morphometrically in 2 mouse models during long period and that compares this course with the natural history in human CMT1A. Taken together, we conclude that C3-PMP mice may be more an appropriate model for CMT1A than C22 mice. C3-PMP mice may be useful to investigate the abnormalities in initial nerve maturation, taking into account the myelin and axon maturation and Schwann cellYaxon interactions. This might yield opportunities for improving myelination early in life, but the main goal should be to reach normal numbers of axons and normal axonal function during nerve maturation. Furthermore, the model is useful to investigate whether improving myelination in adult mice might be sufficient to restore axonal function. C22 mice may, nevertheless, be a useful model for the severe part of the CMT1 spectrum, including Déjerine-Sottas syndrome and hereditary hypomyelinating neuropathy.
